Targets

PI3K

4 articles

Medicinal ChemistryBioorganic & Medicinal Chemistry

Pyrazolopyrimidine scaffold yields dual PI3K/HDAC6 inhibitors active across breast cancer subtypes

  • Pairing PI3K and HDAC inhibition on a pyrazolo[3,4-d]pyrimidine core targets crosstalk between the PI3K/AKT pathway and epigenetic dysregulation in breast cancer.
  • Lead compound 13k inhibits PI3Kα at sub-micromolar potency and HDAC6 at low-nanomolar potency; pharmacophore modeling, docking and molecular dynamics rationalized the SAR.
  • In ER+, HER2+ and triple-negative lines it curbed proliferation, migration and invasion, and triggered apoptosis and G1 arrest; predicted ADMET looked drug-like.
PointsBased on the abstract

Unlike CUDC-907, which hits class I HDACs plus PI3K, 13k leans on HDAC6, a cleaner and likely better-tolerated profile if the selectivity holds. But I'd want a PI3Kα/β/δ/γ and HDAC1/2/3 panel, plus cellular readouts (p-AKT, acetyl-tubulin versus acetyl-H3) to prove on-target engagement. Cell data in three subtypes with only predicted ADMET means hydroxamate PK and mutagenicity are still untested.

PharmacologyACS Pharmacology & Translational Science

Pseudolaric acids A and B show neuroprotective signals in cells and an AlCl3 Alzheimer's mouse model

  • Pseudolaric acids A and B were tested against Aβ25–35-induced PC12 apoptosis and LPS-stimulated BV2 microglia and RAW264.7 macrophages.
  • In vitro, anti-apoptotic effects were linked to IRS-1/Akt/GSK-3β signaling and anti-inflammatory effects to NF-κB and miR-155.
  • In an AlCl3-induced mouse model, pseudolaric acid B improved spatial learning and memory in the water maze.
PointsBased on the abstract

Weak translational chain: Aβ25–35 on PC12 cells and an aluminium-chloride mouse are poor predictors of human Alzheimer's, and the authors concede the mechanisms are not confirmed in vivo. Pseudolaric acid B is also a cytotoxic microtubule-destabilising agent, so the window between neuroprotective and toxic exposure, plus any brain penetration data, matters more than another pathway readout. A transgenic model with PK would be the next step.

PharmacologyBiochemical Pharmacology

Natural-product-derived β-carboline D14 curbs glioma by inhibiting SRC

  • Starting from a plant alkaloid with known antitumor activity, the authors built a scalable total synthesis and made a series of nineteen analogues; D14 was the most cytotoxic across glioma lines, including patient-derived primary cells.
  • Computational screening, dynamics and thermal-shift assays pointed to SRC as the target, with binding near Gln147 and reduced SRC phosphorylation, dampening PI3K/AKT and STAT3 signaling.
  • In an orthotopic mouse glioma model, D14 slowed tumor growth without evident organ toxicity.
PointsBased on the abstract

Nineteen analogues, one winner, and a target call resting mostly on docking, dynamics and a thermal shift: I wouldn't call SRC the mechanism yet. Without kinome selectivity and a Gln147 mutant, this could be polypharmacology. And orthotopic GL261 is forgiving; show brain exposure across the BBB and a real margin over the cytotoxic dose.

Medicinal ChemistryJournal of Medicinal Chemistry (ACS)

Wild-Type-Sparing PI3Kα H1047R Inhibitors Identified from Quinazolinone Series

  • Approved PI3Kα inhibitors for HR+/HER2− PIK3CA-mutated breast cancer cause dose-limiting hyperglycemia and other adverse effects linked to inhibition of wild-type PI3Kα.
  • Researchers designed a series of tetrasubstituted quinazolin-4(3H)-one compounds intended to selectively inhibit the oncogenic PI3Kα H1047R mutant.
  • Selectivity for the mutant enzyme over wild-type PI3Kα is proposed to stem from a slow-on, slow-off binding mechanism.
  • Lead compound 34 showed potent, mutant-selective activity in vitro along with a favorable ADME profile.
  • In a T47D xenograft mouse model, compound 34 produced significant tumor growth inhibition without affecting blood glucose or serum insulin levels, unlike a benchmark approved PI3Kα inhibitor.
  • The authors note that further optimization of compound 34 is needed to lower the efficacious dose and improve tolerability.
PointsBased on the abstract

Alpelisib's hyperglycemia problem is the elephant in every PI3Kα SAR discussion — it's the reason dose reductions dog that drug in clinic, tracing straight back to wild-type inhibition in normal insulin signaling. A slow-on, slow-off kinetic selectivity mechanism here is more interesting than a static pocket-shape argument: if H1047R's altered conformational dynamics let this quinazolinone linger on mutant enzyme while it washes out of WT, that's a residence-time story I'd want kinITC and washout kinetics to confirm before fully believing. Tetrasubstituted quinazolinones aren't an exotic scaffold to make, which helps for a program needing heavy analoging around that pocket. Clean xenograft efficacy without glucose/insulin perturbation is the proof-of-concept that matters — but the authors' own admission that compound 34 needs a lower efficacious dose and better tolerability is the real tell: promising probe, not yet a candidate.